Rohit Goel serves as Manager and Principal Accounting Officer of the Company. Mr. Goel is responsible for all accounting matters relating to the Company. His previous experience includes leading USGAAP audit teams and leading or assisting in the statutory audit of limited and private companies in various industries including telecom, stock brokerage, manufacturing, education, banking and digital marketing. He has worked on preparing process, workflow, implementation of SAP based accounting systems, worked on several accounting projects for clients based in US, Spain and UK, and assisted an audit team that conducted an asset audit for clients in Africa. In 2012 and 2013 he passed the CA CPT and CA IPCC exams. From September 2013 to March 2014 he worked as a Chartered Accountant (CA) trainee for Mahesh K Aggarwal & Co. And from April 2014 to September 11, 2016 he worked as a Chartered Accountant trainee, with AJSH & Co. In September 2016, he founded BnA Consultancy to provide accounting, taxation and statutory compliance services. In 2015, Mr. Goel graduated with a Bachelor of Commerce (Hons) from Delhi University, India. He is currently pursuing the CPA license and a Master of Commerce at Indira Gandhi National Open University (IGNOU), India. Mr. Goel is based in India along with the rest of the accounting team.
As the Manager and Principal Accounting Officer of IGC Pharma Inc, the total compensation of Rohit Goel at IGC Pharma Inc is $41,000. There are 4 executives at IGC Pharma Inc getting paid more, with Ram Mukunda having the highest compensation of $801,000.
Rohit Goel is 25, he's been the Manager and Principal Accounting Officer of IGC Pharma Inc since 2017. There are 6 older and no younger executives at IGC Pharma Inc. The oldest executive at IGC Pharma Inc is Richard Prins, 62, who is the Independent Chairman of the Board.
Over the last 17 years, insiders at IGC Pharma Inc have traded over $12,397,736 worth of IGC Pharma Inc stock and bought 1,543,722 units worth $473,972 . The most active insiders traders include Ram Mukunda, Steven Michael Oliveira und Zwirn & Co., L.P.Zwirn Dani.... On average, IGC Pharma Inc executives and independent directors trade stock every 143 days with the average trade being worth of $93,624. The most recent stock trade was executed by Ram Mukunda on 13 March 2024, trading 1,184,585 units of IGC stock currently worth $443,627.
igc is developing a product portfolio of phytocannabinoid-based therapies through leading edge research for the treatment of a wide range of therapeutic indications. these include neuropathic and cancer pain, epilepsy, end of life supportive care, adjunctive supportive therapies of chronic neurological and oncological diagnosis, which are life altering or life threatening our mission is to treat pain, ptsd, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions with phytocannabinoid-based treatments
IGC Pharma Inc executives and other stock owners filed with the SEC include: